Treatment of drug-eluting stents in-stent restenosis with XXXX -coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.

@entity1 @entity75 @entity1311 @entity453 @entity299 @entity583 @entity204
BACKGROUND: Data about @entity1311 -eluting balloon (PCB) angioplasty to treat drug-eluting stents (DES) in-stent restenosis (ISR) were mainly collected in selected @entity1 populations in the setting of randomized trials. The main goal of this prospective registry was to confirm the positive findings of these studies in an unselected population in clinical practice. METHODS: Consecutive @entity1 with DES-ISR treated by PCB angioplasty were recruited in this prospective real-world registry. The primary endpoint was clinically driven @entity75 revascularization (TLR) at 9months. Secondary endpoints included acute technical success, in-hospital outcomes, 9-month major adverse @entity299 (MACE) a composite of @entity204 , @entity583 ( @entity583 ) and TLR and the occurrence of target vessel revascularization. RESULTS: A total of 206 @entity1 (67.7  10.2years, 80.6% male, 41.3% diabetics) with 210 lesions were recruited. Unstable @entity453 was present in 55.3% of @entity1 . The time from DES implantation to DES-ISR was 3.0  2.4years. Quantitative analyses revealed that patterns of treated DES-ISR were focal in 55.7% and diffuse in 44.3%. The reference diameter was 2.76  0.64mm. The 9-month follow-up rate was 90.8% (187/206). At 9months, the TLR rate was 7.0% (13/187) whereas the rates for MACE, @entity583 and @entity204 were 10.7% (20/187), 4.8% (9/187) and 2.1% (4/187) respectively. Results were consistent in @entity1 with @entity1311 and non- @entity1311 -eluting stents (PES) ISR. CONCLUSION: This large prospective registry demonstrated acceptable rates of TLR and MACE at 9months after treatment of DES-ISR by PCB angioplasty. PCB angioplasty was equally effective in @entity1 with PES-ISR and non PES-ISR.
